“Our biosimilar candidate is the only one referencing Cimzia that is under development globally and the reference product has carved out significant market share as treatment for chronic rheumatic diseases, especially for women of childbearing age. I’m very pleased to add it to our expanding commercial partnership with Advanz Pharma,” says Róbert Wessman, Chairman and CEO of Alvotech.

Certolizumab pegol

Certolizumab pegol is a TNF-alpha inhibitor indicated for a variety of inflammatory diseases. Worldwide sales of Cimzia in 2024 were US$2.3 billion.

Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in Europe in Q4 2025.